Nobody puts cancer in a corner!

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Experts discussed supportive care and why it should be integrated into standard oncology care.

The Aliya PEF ablation procedure achieved local tumor control in 96% of patients and was well-tolerated with no delays to SOC therapy.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.